Skip to content

OÜ Medpharma

Registry code (registrikood) 12200075Private limited company (Osaühing)VAT EE101548872Activity (EMTAK 46461): Ravimite ja muude apteegikaupade hulgimüükActive

Tallinn, Harju County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€1.2M
▲ 378.5% vs 2024
Profit before tax (2025)
-€73k
Employees, FTE (2025)
2
State taxes paid, last 4 quarters
€388k

Revenue, profit and employees, 2019–2025

€02019€02020€02021€02022€211k2023€242k2024€1.2M2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2019€0-€72-€72€3,0710
2020€0-€9,795-€10,244-€7,1730
2021€0-€11,507-€13,459-€20,6320
2022—-€2,009-€4,031€9760
2023€211,318€3,983€3,257€9,2330
2024€241,591€8,690€9,418€18,6510
2025€1,156,024-€54,806-€73,334-€54,6832

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2019—€3,071——€3,071
2020€9,788€14,292€1,016€20,449-€7,173
2021€3,648€6,769€0€27,401-€20,632
2022€853€976—€0€976
2023€22,500€47,777€38,544—€9,233
2024€42,332€213,340€194,689—€18,651
2025€105,405€1,242,856€979,006€318,533-€54,683

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1——€0—
2022 Q2——€0—
2022 Q3€0€0€0—
2022 Q4——€0—
2023 Q1€314€340€01
2023 Q2€1,276€1,020€8,3931
2023 Q3€9,897€1,020€132,3381
2023 Q4€9,811€1,020€117,3611
2024 Q1€4,601€1,020€47,4221
2024 Q2€2,856€943€41,6311
2024 Q3€1,982€1,020€43,4321
2024 Q4€8,423€1,020€91,4622
2025 Q1€15,954€6,017€401,5083
2025 Q2€32,875€17,160€205,5214
2025 Q3€42,151€19,039€444,3633
2025 Q4€85,142€17,721€1,006,2674
2026 Q1€127,849€18,148€1,189,1184
2026 Q2€83,445€11,367€661,4243
2026 Q3€91,209€13,266€948,1833

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), OÜ Medpharma reported revenue of €1,156,024.

The company recorded a net loss of €73,334 in the 2025 financial year.

Revenue increased by 378.5% from €241,591 in 2024 to €1,156,024 in 2025.

Equity accounted for -4.4% of total assets of €1,242,856 at the end of the 2025 reporting period.

With 2 full-time-equivalent employees in 2025, revenue per employee was €578,012.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, OÜ Medpharma reported €3,804,992 in turnover.

EMTA recorded 3 employees for the quarter ending Q3 2026, compared with 2 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.